Schrodinger, Inc.

Schrodinger, Inc. reported a significant turnaround in Q2 2026, achieving a net income of $5.98 million compared to a substantial loss in the prior year. Total revenues increased to $58.89 million, driven by strong growth in drug discovery revenue, despite a decline in software product and services revenue. The company also saw a positive change in the fair value of equity investments, contributing to the improved financial performance.

Schrodinger, Inc. reported strong second-quarter 2026 financial results, achieving a net income of $6.0 million, a significant improvement from a net loss of $43.2 million in the prior year. Total revenue increased 8% to $58.9 million, driven by a 27% rise in Annual Contract Value (ACV) to $29.6 million and a substantial increase in drug discovery revenue due to a collaboration milestone. The company also launched Bunsen, its new AI co-scientist, and secured a strategic software agreement with Bristol Myers Squibb, while raising its full-year drug discovery revenue guidance.

Schrodinger, Inc. received a cash payment of approximately $57 million following the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc. Schrodinger had co-founded Ajax Therapeutics. The company is also eligible for additional cash payments contingent on Ajax achieving specific clinical and regulatory milestones.

Schrodinger, Inc. stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 3,000,000. This amendment was approved at the Annual Meeting held on June 22, 2026. Additionally, stockholders elected three Class III directors, approved the advisory vote on executive compensation, and ratified KPMG LLP as the independent auditor for 2026.

Schrodinger, Inc. entered into a transition, separation, and release of claims agreement with Mannix Aklian, its former Chief Commercial Officer, Global Head of Software Sales and Marketing, on June 5, 2026. This agreement confirms the terms of his separation, providing him with nine months of salary continuation payments and 12 months of COBRA premium payments. Additionally, Mr. Aklian will receive various bonus payments totaling $88,096 and an acceleration of vesting for a portion of his restricted stock unit award scheduled for July 2026.

Schrödinger, Inc. announced that Mannix Aklian ceased his role as Chief Commercial Officer, Global Head of Software Sales and Marketing, effective May 18, 2026. Paul Davie, the company's former Executive Vice President, Sales, has returned as interim Chief Commercial Officer while a search for a permanent replacement is conducted. Additionally, the company reaffirmed its full-year and second quarter 2026 financial and operational guidance.

Schrodinger, Inc. reported a net loss of $(60.0) million for the first quarter of 2026, a slight increase from $(59.8) million in the prior year period. Total revenues decreased by 1.6% to $58.6 million, primarily due to a 20.9% decline in software products and services revenue. This was partially offset by a substantial 123.5% increase in drug discovery revenue. The company also experienced a significant swing in operating cash flow, moving from $144.1 million provided in Q1 2025 to $(14.8) million used in Q1 2026.

Schrödinger announced that Lilly will acquire Ajax Therapeutics, a company co-founded by Schrödinger with a 5.8% equity stake, for up to $2.3 billion, validating its computational platform. For Q1 2026, the company reported a net loss of $60.0 million on total revenue of $58.6 million, a 2% decrease year-over-year. ACV grew 12% to $28.4 million, while software revenue decreased 21% due to a planned transition to hosted licensing. Schrödinger also plans to launch Bunsen, an agentic AI co-scientist, this summer and maintained its 2026 financial guidance.

Schrodinger, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 22, 2026. Stockholders will vote on the election of three Class III directors, an advisory resolution on executive compensation, and the ratification of KPMG LLP as the independent auditor for 2026. Additionally, the company proposes an amendment to its 2022 Equity Incentive Plan to increase the number of shares available for issuance by 3,000,000 shares.